Biology:Retagliptin
From HandWiki
Short description: Chemical compound
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H18F6N4O3 |
Molar mass | 464.368 g·mol−1 |
3D model (JSmol) | |
| |
|
Retagliptin is a DPP-4 inhibitor studied for the treatment of type 2 diabetes.[1][2][3]
Refences
- ↑ Meng, Xiangjun; Cai, Lanlan; Ren, Tianming; Sun, Dong; Gu, Jingkai (2018). "Simultaneous quantitative analysis of retagliptin and its main active metabolite in human multiple matrices by liquid chromatography tandem mass spectrometry" (in en). Analytical Methods 10 (18): 2108–2114. doi:10.1039/C8AY00040A. ISSN 1759-9679. https://pubs.rsc.org/en/content/articlelanding/2018/ay/c8ay00040a.
- ↑ Hu, Chao; Zheng, Jing; Miao, Jia; Liu, Fang; Hu, Ting-Ting; Gu, Jing-Kai; Shu, Shi-Qing; Wang, Ying et al. (2018). "[Pharmacokinetics of Phosphate Retagliptin Tabletin in Patients with Renal Dysfunction"]. Sichuan da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition 49 (1): 74–80. ISSN 1672-173X. PMID 29737094. https://pubmed.ncbi.nlm.nih.gov/29737094/.
- ↑ Cahn, Avivit; Cernea, Simona; Raz, Itamar (2016). "An update on DPP-4 inhibitors in the management of type 2 diabetes". Expert Opinion on Emerging Drugs 21 (4): 409–419. doi:10.1080/14728214.2016.1257608. PMID 27809608.
Original source: https://en.wikipedia.org/wiki/Retagliptin.
Read more |